311 related articles for article (PubMed ID: 25485532)
21. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling.
Brase JC; Johannes M; Mannsperger H; Fälth M; Metzger J; Kacprzyk LA; Andrasiuk T; Gade S; Meister M; Sirma H; Sauter G; Simon R; Schlomm T; Beissbarth T; Korf U; Kuner R; Sültmann H
BMC Cancer; 2011 Dec; 11():507. PubMed ID: 22142399
[TBL] [Abstract][Full Text] [Related]
22. Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer.
Leinonen KA; Tolonen TT; Bracken H; Stenman UH; Tammela TL; Saramäki OR; Visakorpi T
Clin Cancer Res; 2010 May; 16(10):2845-51. PubMed ID: 20442300
[TBL] [Abstract][Full Text] [Related]
23. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
Hofer MD; Kuefer R; Maier C; Herkommer K; Perner S; Demichelis F; Paiss T; Vogel W; Rubin MA; Hoegel J
Cancer Res; 2009 Jan; 69(2):640-6. PubMed ID: 19147579
[TBL] [Abstract][Full Text] [Related]
24. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
[TBL] [Abstract][Full Text] [Related]
25. Androgen regulation of ETS gene fusion transcripts in prostate cancer.
Gasi D; Trapman J
Methods Mol Biol; 2011; 776():335-48. PubMed ID: 21796535
[TBL] [Abstract][Full Text] [Related]
26. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.
Nam RK; Sugar L; Wang Z; Yang W; Kitching R; Klotz LH; Venkateswaran V; Narod SA; Seth A
Cancer Biol Ther; 2007 Jan; 6(1):40-5. PubMed ID: 17172822
[TBL] [Abstract][Full Text] [Related]
27. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.
Luedeke M; Linnert CM; Hofer MD; Surowy HM; Rinckleb AE; Hoegel J; Kuefer R; Rubin MA; Vogel W; Maier C
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3030-5. PubMed ID: 19861517
[TBL] [Abstract][Full Text] [Related]
28. Rapid and Sensitive Fusion Gene Detection in Prostate Cancer Urinary Specimens by Label-Free Surface-enhanced Raman Scattering.
Koo KM; McNamara B; Wee EJH; Wang Y; Trau M
J Biomed Nanotechnol; 2016 Sep; 12(9):1798-805. PubMed ID: 29345891
[TBL] [Abstract][Full Text] [Related]
29. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Helgeson BE; Tomlins SA; Shah N; Laxman B; Cao Q; Prensner JR; Cao X; Singla N; Montie JE; Varambally S; Mehra R; Chinnaiyan AM
Cancer Res; 2008 Jan; 68(1):73-80. PubMed ID: 18172298
[TBL] [Abstract][Full Text] [Related]
30. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
Tomlins SA; Mehra R; Rhodes DR; Smith LR; Roulston D; Helgeson BE; Cao X; Wei JT; Rubin MA; Shah RB; Chinnaiyan AM
Cancer Res; 2006 Apr; 66(7):3396-400. PubMed ID: 16585160
[TBL] [Abstract][Full Text] [Related]
31. Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma.
Wang L; Williamson SR; Zhang S; Huang J; Montironi R; Davison DD; Wang M; Yao JL; Lopez-Beltran A; Osunkoya AO; MacLennan GT; Baldridge LA; Du X; Cheng L
Mol Carcinog; 2015 Sep; 54(9):900-7. PubMed ID: 24777847
[TBL] [Abstract][Full Text] [Related]
32. Whole-transcriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer.
Chow A; Amemiya Y; Sugar L; Nam R; Seth A
Anticancer Res; 2012 Sep; 32(9):3629-41. PubMed ID: 22993300
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
[TBL] [Abstract][Full Text] [Related]
34. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients.
Lee K; Chae JY; Kwak C; Ku JH; Moon KC
Urology; 2010 Nov; 76(5):1268.e7-13. PubMed ID: 20800881
[TBL] [Abstract][Full Text] [Related]
35. Molecular Composition of Genomic
Krumbholz M; Agaimy A; Stoehr R; Burger M; Wach S; Taubert H; Wullich B; Hartmann A; Metzler M
Dis Markers; 2019; 2019():5085373. PubMed ID: 31915468
[TBL] [Abstract][Full Text] [Related]
36. Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity.
Attard G; Jameson C; Moreira J; Flohr P; Parker C; Dearnaley D; Cooper CS; de Bono JS
J Clin Pathol; 2009 Apr; 62(4):373-6. PubMed ID: 19066166
[TBL] [Abstract][Full Text] [Related]
37. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.
Rubin MA; Chinnaiyan AM
Lab Invest; 2006 Nov; 86(11):1099-102. PubMed ID: 16983328
[TBL] [Abstract][Full Text] [Related]
38. Molecular biology underlying the clinical heterogeneity of prostate cancer: an update.
Mackinnon AC; Yan BC; Joseph LJ; Al-Ahmadie HA
Arch Pathol Lab Med; 2009 Jul; 133(7):1033-40. PubMed ID: 19642730
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis.
Yao Y; Wang H; Li B; Tang Y
Tumour Biol; 2014 Mar; 35(3):2157-66. PubMed ID: 24142545
[TBL] [Abstract][Full Text] [Related]
40. High-speed biosensing strategy for non-invasive profiling of multiple cancer fusion genes in urine.
Koo KM; Wee EJH; Trau M
Biosens Bioelectron; 2017 Mar; 89(Pt 2):715-720. PubMed ID: 27865106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
